Lung cancer is a complex, genetically heterogeneous disease. It is the most common cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) represents the majority of the diagnosed lung cancer cases. Osimertinib is a new treatment option that demonstrated a superior efficacy over standard epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) or platinum-based chemotherapy. The safety and efficacy of osimertinib (a third generation EGFR-TKIs) were confirmed by well-designed clinical trials. Consequently, osimertinib was considered a first-line treatment option, particularly in patients with EGFR mutant NSCLC. It has been approved by FDA for the treatment of advance or metastatic NSCLC patients with specific EGFR-mutant NSCLC. As an active member of the multidisciplinary team, pharmacist has a promising role in assuring safe, effective and cost-effective treatment in patient with NSCLC. This review article aims to highlight the latest evidence about osimertinib use as a new treatment option in the clinical practice and to review the potential pharmacist key roles in NSCLC patient care.
HeinemanDJDanielsJMSchreursWH.Clinical staging of Nsclc: current evidence and implications for adjuvant chemotherapy. Therapeutic Adv Med Oncol2017;
9: 599–609.
2.
BrayFFerlayJSoerjomataramI, et al.
Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin2018;
68: 394–424.
3.
Sosa IglesiasVGiurannoLDuboisLJ, et al.
Drug resistance in non-small cell lung cancer: a potential for notch targeting?Frontier Oncol2018;
8: 267.
4.
ZappaCMousaSA.Non-small cell lung cancer: current treatment and future advances. Translational Lung Cancer Res2016;
5: 288.
5.
LiZ-XZhaoWSunQ, et al.
Efficacy of osimertinib for the treatment of previously Egfr Tki treated Nsclc patients: a meta-analysis. Clin Translat Oncol2020; 22(6): 892–899.
6.
YonedaKImanishiNIchikiY, et al.
Treatment of non-small cell lung cancer with Egfr-mutations. J UOEH2019;
41: 153–163.
7.
HirashimaTSatouchiMHidaT, et al.
Osimertinib for Japanese patients with T790m‐positive advanced non‐small‐cell lung cancer: a pooled subgroup analysis.Cancer Sci2019;
110: 2884.
8.
XingPMuYHaoX, et al.
Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis. Clin Translat Oncol2019; 21(10): 1424–1431.
9.
ZhangHChenJLiuT, et al.
First-line treatments in Egfr-mutated advanced non-small cell lung cancer: a network meta-analysis. PloS One2019; 14(10): e0223530.
10.
FangWHuangYHongS, et al.
Egfr Exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer. BMC Cancer2019;
19: 595.
11.
LeonettiASharmaSMinariR, et al.
Resistance mechanisms to osimertinib in Egfr-mutated non-small cell lung cancer. Br J Cancer2019; 121(9): 725–737.
12.
GirardN.Optimizing outcomes and treatment sequences in Egfr mutation-positive non-small-cell lung cancer: recent updates. Future Oncol2019;
15: 2983–2997.
13.
GreigSL.Osimertinib: first global approval. Drugs2016;
76: 263–273.
14.
JiangTSuCRenS, et al.
A consensus on the role of osimertinib in non-small cell lung cancer from the Ame Lung Cancer Collaborative Group. J Thoracic Dis2018;
10: 3909.
15.
LinJ-ZMaS-KWuS-X, et al.
A network meta-analysis of nonsmall-cell lung cancer patients with an activating Egfr mutation: should osimertinib be the first-line treatment?Medicine2018; 97(30): e11569.
16.
WuBGuXZhangQ.Cost-effectiveness of osimertinib for Egfr mutation–positive non–small cell lung cancer after progression following first-line Egfr Tki therapy. J Thoracic Oncol2018;
13: 184–93.
17.
RamalingamSSVansteenkisteJPlanchardD, et al.
Overall survival with osimertinib in untreated, Egfr-mutated advanced NSCLC. New Engl J Med2020: 382(1): 41–50.
18.
J¨annePAYangJCKimDW, et al.
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.N Engl J Med2015;
372: 1689–1699.
19.
YangJCAhnM-JKimD-W, et al.
Osimertinib in pretreated T790M-positive advanced non–small-cell lung cancer: AURA Study Phase II Extension Component. J Clin Oncol 2017; 35(12): 1288–1296.
20.
MokTSWuY-LAhnMJ, et al.
Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med2017;
376: 629–640.
21.
SoriaJ-COheYVansteenkisteJ, et al.
Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med2018;
378:113–125.
22.
WuYLHerbstRSMannH, et al.
ADAURA: Phase III, double-blind, randomized study of osimertinib versus placebo in EGFR mutation-positive early-stage NSCLC after complete surgical resection.Clin Lung Cancer2018;
19: e533–e536.
JiangTSuCLiX, et al.
EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases.J Thorac Oncol2016;
11: 1718–1728.
25.
MagnusonWJLester-CollNHWuAJ, et al.
Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis. J Clin Oncol2017;
35: 1070–1077.
26.
KhozinSWeinstockCGideonM, et al.
Osimertinib for the treatment of metastatic EGFR T790M mutation–positive non–small cell lung cancer.Clin Cancer Res2017;
23: 2131–2135.
27.
ShinELimDHHanJ, et al.
Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors.BMC Ophthalmol2020;
20: 19, https://doi.org/10.1186/s12886-019-1285-9
28.
VishwanathanKDickinsonPASoK, et al.
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.Br J Clin Pharmacol2018;
84: 1156–1169.
29.
HarveyRDIsambertNRafiiS, et al.
Effect of multiple-dose osimertinib (AZD9291) on the pharmacokinetics (PK) of simvastatin and rosuvastatin. J Clin Oncol2016;
34: e14098–e14098.
30.
VishwanathanKDickinsonPABuiK, et al.
Abstract B153: effect of food and gastric pH modifiers on the pharmacokinetics of AZD9291. Mol Cancer Ther2015;
14: B153.
31.
HollemanMSAlMJZaimR, et al.
Cost‑effectiveness analysis of the frst‑line EGFR‑TKIs in patients with non‑small cell lung cancer harbouring EGFR mutations. Eur J Health Econ2019, https://doi.org/10.1007/s10198-019-01117-3
32.
AguiarPNHaalandBParkW, et al.
Cost-effectiveness of osimertinib in the first-line treatment of patients with Egfr-mutated advanced non–small cell lung cancer. JAMA Oncology2018;
4: 1080–1084.
33.
WangQYangSWangK, et al.
Met inhibitors for targeted therapy of Egfr Tki-resistant lung cancer. J Hematol Oncol2019;
12: 63.
34.
LeTGerberDE.Newer-generation Egfr inhibitors in lung cancer: how are they best used?Cancers2019;
11: 366.
35.
Witt EA, Shafer E, Staskon F, et al. An evaluation of a local oncology specialized pharmacists’ training program in non-small cell lung cancer. J Drug Assess 2018; 7: 12.
36.
KhrystolubovaNShiehMPatelAJ, et al.
Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting.J Oncol Pharm Practice2020;
26: 13–22.
37.
FornasierG, et al.
Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance.Int J Clin Pharm2018;
40: 795–802.
38.
GreerJAAmoyalNNisotelL, et al.
A systematic review of adherence to oral antineoplastic therapies.Oncologist2016;
21: 354–376.
39.
MacklerESegalEMMulunehB, et al.
2018 Hematology/Oncology Pharmacist Association best practices for the management of oral oncolytic therapy: pharmacy practice standard.J Oncol Pract2019;
15: e346–e355.
40.
HoughSRomanA. The evolving landscape of ALK inhibitors in non–small cell lung cancer: opportunities for pharmacists to optimize treatment selection. Specialty Pharmacy Times, August 2019.
41.
HirshVBlaisNBurkesR, et al.
Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors.Curr Oncol2014;
21: 329–336, https://doi.org/10.3747/co.21.2241
